Ranpura Sandeep, Maralingannavar Vishwanathgouda, Gheorghe Alexandra-Gabriela, Ma Edward, Morrissey James, Betenbaugh Michael J, Demirhan Deniz
Lonza Biologics plc, Slough, United Kingdom.
Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States.
Comput Struct Biotechnol J. 2025 Jun 23;27:2796-2813. doi: 10.1016/j.csbj.2025.06.035. eCollection 2025.
Recent advancements in biologics production using CHO cells have been partly driven by improved understanding of how variations in the cell culture environment influence cellular metabolism, productivity, and the attributes of the final product. In-silico models serve a valuable role in mapping the effects of various process parameters and media changes on cellular response. Advances in technologies such as data-driven analysis, self-learning systems, and digital twins are reinforcing progress toward smart manufacturing, enabling the real-time control of production processes. Furthermore, kinetic, and constraint-based mechanistic modeling, combined with omics approaches, are becoming increasingly incorporated into the bioprocess development and manufacturing innovation ecosystem. In this review, we cover CHO central metabolism as a foundation for mechanistic modeling and extend the discussion to include various mechanistic modeling approaches, highlighting the incorporation of glycosylation and secretory pathways. Multi-omics approaches provide a deeper understanding of intracellular processes and the dynamic interactions between product quality and pathways. In parallel, to achieve the Industry 4.0 vision of digitalization and machine learning techniques are finding wider adoption in biopharmaceutical development. We discuss the potential applications of these techniques for predictions, inference, optimization, and control. The role of big data analytics and artificial intelligence methods in reinforcing progress towards smart manufacturing and enabling real-time control of production processes is discussed. Finally, we summarize the application of machine learning and hybrid models to CHO bioprocesses, aiming to develop and manufacture drugs more efficiently and at a lower cost for patients.
使用CHO细胞进行生物制品生产的最新进展,部分得益于对细胞培养环境变化如何影响细胞代谢、生产力以及最终产品属性的更深入理解。计算机模拟模型在描绘各种工艺参数和培养基变化对细胞反应的影响方面发挥着重要作用。数据驱动分析、自学习系统和数字孪生等技术的进步正在推动向智能制造迈进,实现生产过程的实时控制。此外,动力学和基于约束的机理建模与组学方法相结合,正越来越多地融入生物工艺开发和制造创新生态系统。在本综述中,我们将CHO细胞的中心代谢作为机理建模的基础,并将讨论扩展到包括各种机理建模方法,重点介绍糖基化和分泌途径的纳入。多组学方法能更深入地了解细胞内过程以及产品质量与途径之间的动态相互作用。与此同时,为实现工业4.0的数字化愿景,机器学习技术在生物制药开发中的应用越来越广泛。我们讨论了这些技术在预测、推理、优化和控制方面的潜在应用。还讨论了大数据分析和人工智能方法在推动智能制造进程以及实现生产过程实时控制方面的作用。最后,我们总结了机器学习和混合模型在CHO生物工艺中的应用,旨在以更低成本更高效地为患者研发和生产药物。